Morphosys AG O.N. (MORG)

33.110
-1.520(-4.39%)
  • Volume:
    295,733
  • Bid/Ask:
    33.090/33.130
  • Day's Range:
    33.010 - 35.035
  • Type:Equity
  • Market:Germany
  • ISIN:DE0006632003
  • WKN:663200

MORG Overview

Prev. Close
33.11
Day's Range
33.01-35.035
Revenue
162.7M
Open
34.765
52 wk Range
32.41-101.9
EPS
-3.18
Volume
295,733
Market Cap
1.13B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
309,970
P/E Ratio
-
Beta
0.74
1-Year Change
-64.69%
Shares Outstanding
34,141,025
Next Earnings Date
Mar 16, 2022
What is your sentiment on Morphosys AG O.N.?
or
Market is currently closed. Voting is open during market hours.

  • MorphoSys Continues To Progress

    At the American Society of Hematology (ASH) annual meeting, compelling early combination data on MOR208 and MOR202 were presented. MOR208 with lenalidomide in previously untreated...

  • MorphoSys: Getting Aggressive On Pipeline

    Getting aggressive on its pipelineMorphoSys (L:0NDV) recently communicated its plans for its proprietary pipeline, which will help transform the company into a fully integrated...

Morphosys AG O.N. Company Profile

Employees
607
Market
Germany

MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer’s diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • from now it will move up above 50 ...
    0
    • Obviously you were wrong.
      0
    • in Aug moved up over 50 and i sold all shares at 49.88... now i dont care
      0
  • I wounder why the stock has been hit so hard? Its almost @50% ot march last year when the entire market crashed!! I dont beleive lowering the upper limit of the FY revenue guidance is the driver. I have to say that ive not spent quality time understanding the fundamental of this company, i only strated to follow it recently. Appreciate your insights. Thanks
    0
    • Any idea?
      0
      • Announced a narrowing of revenue guidance. There are better options out there, but today might be a good entry point as the negative reaction (incl. yesterday) seems excessive.
        0
    • https://ch.marketscreener.com/kurs/aktie/MORPHOSYS-AG-436425/news/COMPANY-TALK-J-J-nbsp-41-Prozent-Plus-mit-Morphosys-Wirkstoff-33013409/
      0
      • strong buy
        0
        • European approval for tafasitamab is due at the end of May
          0
          • Damn good results published!!!
            0
            • When (what time)  is the news public concerning their yearresults?
              0
              • buy buy buy
                0
                • i buy today , target 150$
                  0
                  • I would like to buy today. is it a good idea?
                    0
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.